Spectral Precise Image Study for Brain Tumors

May 27, 2026 updated by: Philips Clinical & Medical Affairs Global

Clinical Study for Exploring Image Quality the Spectral Precise Image in Patients With Diagnosed Intracranial Tumors

The goal of this observational study is to explore the image quality of spectral CT deep learning reconstruction technology (Spectral Precise Image) of patients with confirmed brain tumors.

The main question it aims to answer is:

The Image Quality (IQ) and diagnostic confidence of Spectral Precise Image reconstructions

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China
        • Recruiting
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Description

Inclusion Criteria:

  1. Patients with clinical and radiology (MRI/CT) diagnosed brain tumors.
  2. Patients who underwent contrast enhanced scans using the Spectral CT 7500.
  3. Study participants with age ≥ 18 years old.
  4. Study participants that have signed Informed Consent Form (ICF)

Exclusion Criteria:

  1. The clinical data or radiological information is considered incomplete after evaluation by the investigator.
  2. Study participant that was enrolled in this study in the past
  3. Data from study participants deemed unsuitable for enrollment based on the investigator's evaluation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective Image quality using Likert score (1-5)
Time Frame: From date of image reconstruction until the date of image reading completion, anticipated 3Months.
Image quality will be assessed by 2 radiologists using Likert score on a scale ranging from 1(poor) to 5(Excellent)
From date of image reconstruction until the date of image reading completion, anticipated 3Months.
Objective Image Quality
Time Frame: From date of image reconstruction until the date of image reading completion, anticipated 3Months.
The objective quality of the image is evaluated by measuring the CT value shown in the image.
From date of image reconstruction until the date of image reading completion, anticipated 3Months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Philips Clinical & Medical Affairs Global

Collaborators

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Investigators

  • Principal Investigator: Jing Wang, 1277 Jiefang Avenue, Wuhan, Hubei Province, P. R. China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 28, 2025

Primary Completion (Estimated)

August 30, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

November 24, 2025

First Submitted That Met QC Criteria

May 27, 2026

First Posted (Actual)

June 2, 2026

Study Record Updates

Last Update Posted (Actual)

June 2, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 301168

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Tumors

Clinical Trials on This is an observational data collection study

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe